Allergan Hits Estimates in Solid Quarter
Allergan (NYS: AGN) reported earnings on May 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Allergan met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share grew significantly.
Margins improved across the board.
Allergan reported revenue of $1.39 billion. The 20 analysts polled by S&P Capital IQ expected to see a top line of $1.38 billion on the same basis. GAAP reported sales were 9.5% higher than the prior-year quarter's $1.27 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.86. The 23 earnings estimates compiled by S&P Capital IQ predicted $0.87 per share. GAAP EPS of $0.74 for Q1 were 45% higher than the prior-year quarter's $0.51 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 85.9%, 30 basis points better than the prior-year quarter. Operating margin was 25.5%, 400 basis points better than the prior-year quarter. Net margin was 16.5%, 400 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $1.51 billion. On the bottom line, the average EPS estimate is $1.09.
Next year's average estimate for revenue is $5.86 billion. The average EPS estimate is $4.19.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 401 members out of 424 rating the stock outperform, and 23 members rating it underperform. Among 112 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 110 give Allergan a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Allergan is outperform, with an average price target of $99.73.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Allergan the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Allergan to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.